FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361006873> ?p ?o ?g. }

• W4361006873 endingPage "877" @default.
• W4361006873 startingPage "877" @default.
• W4361006873 abstract "The introduction of the so-called immune checkpoint inhibitors (ICIs) substantially changed the history of cancer therapy. On the other hand, they can induce the development of rheumatic immune-related adverse events (Rh-irAEs). In the scenario of a joint oncology/rheumatology outpatient clinic, we conducted a single-centre descriptive study to define from a laboratory, clinical and therapeutic point of view, rheumatic conditions developed during anti-PD1 treatment. The study included 32 patients (M/F 16/16, median age 69, IQR 16.5). According to the international classification criteria, eight patients could be classified as affected by Rheumatoid Arthritis, one by Psoriatic Arthritis, six by Polymyalgia Rheumatica, five by systemic connective tissue diseases (two systemic lupus erythematosus, two Sjögren’s syndrome, one undifferentiated connective tissue disease). The remaining patients were diagnosed as having undifferentiated arthritis or inflammatory arthralgia. The median interval between ICIs starting and the onset of symptoms was 14 weeks (IQR 19.75). Moving to treatment, the longitudinal observation revealed that all RA, PsA and CTD patients required the introduction of treatment with DMARDs. In conclusion, the growing use of ICIs in a real-life setting confirmed the possible development of different rheumatological conditions, further emphasising the need for shared oncology/rheumatology management." @default.
• W4361006873 created "2023-03-30" @default.
• W4361006873 creator A5008721254 @default.
• W4361006873 creator A5009650068 @default.
• W4361006873 creator A5010526872 @default.
• W4361006873 creator A5025723323 @default.
• W4361006873 creator A5034918533 @default.
• W4361006873 creator A5051526168 @default.
• W4361006873 creator A5063498618 @default.
• W4361006873 creator A5085432815 @default.
• W4361006873 creator A5089912115 @default.
• W4361006873 date "2023-03-25" @default.
• W4361006873 modified "2023-09-25" @default.
• W4361006873 title "Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study" @default.
• W4361006873 cites W2060070314 @default.
• W4361006873 cites W2083180635 @default.
• W4361006873 cites W2112929305 @default.
• W4361006873 cites W2128952811 @default.
• W4361006873 cites W2152897456 @default.
• W4361006873 cites W2156353875 @default.
• W4361006873 cites W2180244775 @default.
• W4361006873 cites W2414564534 @default.
• W4361006873 cites W2560367415 @default.
• W4361006873 cites W2565782504 @default.
• W4361006873 cites W2572174216 @default.
• W4361006873 cites W2592144107 @default.
• W4361006873 cites W2747028021 @default.
• W4361006873 cites W2762010572 @default.
• W4361006873 cites W2886385571 @default.
• W4361006873 cites W2889317689 @default.
• W4361006873 cites W2922883744 @default.
• W4361006873 cites W2945590213 @default.
• W4361006873 cites W2951095160 @default.
• W4361006873 cites W2966041078 @default.
• W4361006873 cites W2997139784 @default.
• W4361006873 cites W3022289262 @default.
• W4361006873 cites W3023683881 @default.
• W4361006873 cites W3045735122 @default.
• W4361006873 cites W3048680533 @default.
• W4361006873 cites W4242982114 @default.
• W4361006873 doi "https://doi.org/10.3390/life13040877" @default.
• W4361006873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37109406" @default.
• W4361006873 hasPublicationYear "2023" @default.
• W4361006873 type Work @default.
• W4361006873 citedByCount "0" @default.
• W4361006873 crossrefType "journal-article" @default.
• W4361006873 hasAuthorship W4361006873A5008721254 @default.
• W4361006873 hasAuthorship W4361006873A5009650068 @default.
• W4361006873 hasAuthorship W4361006873A5010526872 @default.
• W4361006873 hasAuthorship W4361006873A5025723323 @default.
• W4361006873 hasAuthorship W4361006873A5034918533 @default.
• W4361006873 hasAuthorship W4361006873A5051526168 @default.
• W4361006873 hasAuthorship W4361006873A5063498618 @default.
• W4361006873 hasAuthorship W4361006873A5085432815 @default.
• W4361006873 hasAuthorship W4361006873A5089912115 @default.
• W4361006873 hasBestOaLocation W43610068731 @default.
• W4361006873 hasConcept C126322002 @default.
• W4361006873 hasConcept C143998085 @default.
• W4361006873 hasConcept C16005928 @default.
• W4361006873 hasConcept C197934379 @default.
• W4361006873 hasConcept C198451711 @default.
• W4361006873 hasConcept C2776015282 @default.
• W4361006873 hasConcept C2776153627 @default.
• W4361006873 hasConcept C2776260265 @default.
• W4361006873 hasConcept C2776670291 @default.
• W4361006873 hasConcept C2776712624 @default.
• W4361006873 hasConcept C2776821229 @default.
• W4361006873 hasConcept C2777077863 @default.
• W4361006873 hasConcept C2777575956 @default.
• W4361006873 hasConcept C2779075594 @default.
• W4361006873 hasConcept C2779134260 @default.
• W4361006873 hasConcept C2780079024 @default.
• W4361006873 hasConcept C3020110884 @default.
• W4361006873 hasConcept C71924100 @default.
• W4361006873 hasConceptScore W4361006873C126322002 @default.
• W4361006873 hasConceptScore W4361006873C143998085 @default.
• W4361006873 hasConceptScore W4361006873C16005928 @default.
• W4361006873 hasConceptScore W4361006873C197934379 @default.
• W4361006873 hasConceptScore W4361006873C198451711 @default.
• W4361006873 hasConceptScore W4361006873C2776015282 @default.
• W4361006873 hasConceptScore W4361006873C2776153627 @default.
• W4361006873 hasConceptScore W4361006873C2776260265 @default.
• W4361006873 hasConceptScore W4361006873C2776670291 @default.
• W4361006873 hasConceptScore W4361006873C2776712624 @default.
• W4361006873 hasConceptScore W4361006873C2776821229 @default.
• W4361006873 hasConceptScore W4361006873C2777077863 @default.
• W4361006873 hasConceptScore W4361006873C2777575956 @default.
• W4361006873 hasConceptScore W4361006873C2779075594 @default.
• W4361006873 hasConceptScore W4361006873C2779134260 @default.
• W4361006873 hasConceptScore W4361006873C2780079024 @default.
• W4361006873 hasConceptScore W4361006873C3020110884 @default.
• W4361006873 hasConceptScore W4361006873C71924100 @default.
• W4361006873 hasIssue "4" @default.
• W4361006873 hasLocation W43610068731 @default.
• W4361006873 hasLocation W43610068732 @default.
• W4361006873 hasLocation W43610068733 @default.
• W4361006873 hasOpenAccess W4361006873 @default.
• W4361006873 hasPrimaryLocation W43610068731 @default.

• next